Evidence map›Paper›PMID 39372460›Full record

ArticleJACC. Advances2024

Trends in Glucagon-Like Peptide-1 Receptor Agonist Social Media Posts Using Artificial Intelligence.

Aamir Javaid, Sruthika Baviriseaty, Rehan Javaid, Ayah Zirikly, Harshita Kukreja, Chang H Kim, Michael J Blaha, Roger S Blumenthal, Seth S Martin, Francoise A Marvel

Abstract read
In one paragraph

Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aamir JavaidCiccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Digital Health Innovation Laboratory, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sruthika BaviriseatyDigital Health Innovation Laboratory, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Whiting School of Engineering, Department of Computer Science, Johns Hopkins University, Baltimore, Maryland, USA.
Rehan JavaidWhiting School of Engineering, Department of Computer Science, Johns Hopkins University, Baltimore, Maryland, USA.
Ayah ZiriklyWhiting School of Engineering, Department of Computer Science, Johns Hopkins University, Baltimore, Maryland, USA.
Harshita KukrejaDigital Health Innovation Laboratory, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Computer Science Department at New York University, NYU Graduate School of Arts & Science, New York, New York, USA.
Chang H KimCiccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Digital Health Innovation Laboratory, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Michael J BlahaCiccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Roger S BlumenthalCiccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Seth S MartinCiccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Digital Health Innovation Laboratory, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Francoise A MarvelCiccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Digital Health Innovation Laboratory, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: fmarvel1@jhmi.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have surged in popularity in recent years, with discussions about their on-label and off-label use spilling into the public forum. No study has analyzed online discussions about GLP-1RAs. Objectives: The purpose of this study was to analyze perceptions of GLP-1RAs on social media. Methods: We analyzed GLP-1RA-related posts on Reddit between May 28, 2013, and June 1, 2023. All posts were identified that included generic or brand names of GLP-1RAs. Post volume on Reddit was compared to search interest on Google over time. An artificial intelligence (AI) pipeline consisting of a semi-supervised natural language processing model (Bidirectional Encoder Representations from Transformers [BERT]), a dimensionality reduction technique, and a clustering algorithm was used to cluster posts into related topics. Discussion sentiment was classified using a pretrained BERT model and assessed qualitatively. Results: 14,390 GLP-1RA-related Reddit posts by 8,412 authors were identified. Ninety-four percent of posts were created after 2021, consistent with search interest trend on Google. We used the AI model to categorize posts into 30 topics which were hierarchically grouped by the model based on shared content. Posts were identified among communities for individuals with diabetes and obesity, as well as for diseases without a Food and Drug Administration-approved indication. Most posts had a negative sentiment using the pretrained model, acknowledging the pretrained model is at risk for misclassifying posts. Conclusions: AI can generate insights on perceptions of GLP-1RAs on social media. Common themes included success stories of improving diabetes and obesity management, struggles with insurance coverage, and questions regarding diet, side effects, and medication administration.

Indexed as

artificial intelligenceGLP-1RAnatural language processingozempicsocial media

Identifiers

PMID39372460
PMCPMC11450939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.